The chronic liver disease in patients with short bowel syndrome
Standard
The chronic liver disease in patients with short bowel syndrome : etiology and treatment. / Reinshagen, K; Adams, R; Trunk, M; Wessel, L M.
in: MINERVA PEDIATR, Jahrgang 61, Nr. 3, 06.2009, S. 273-81.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - The chronic liver disease in patients with short bowel syndrome
T2 - etiology and treatment
AU - Reinshagen, K
AU - Adams, R
AU - Trunk, M
AU - Wessel, L M
PY - 2009/6
Y1 - 2009/6
N2 - Short bowel syndrome is a life threatening disease with a high mortality and morbidity. Since home parenteral nutrition (PN) has been established, there is an increasing number of patients surviving the acute loss of bowel function. But on the long-time these patients suffer from different complications of PN, with loss of central venous access, recurrent sepsis and finally the syndrome of progressive cholestatic liver disease. Both loss of central venous access and especially the progressive cholestatic liver disease are the limiting factor for the long-term survival of patients suffering from intestinal failure. Interestingly, the pathophysiologic mechanisms of PN induced intrahepatic cholestasis have not been dissolved yet and seem to be of multifactorial genesis. Cholestasis has shown to be associated with prematurity, recurrent sepsis, enteral and PN, especially with lipid emulsions. Enteral feeding and a well-controlled regime of PN lower the incidence of end-stage liver disease and, therefore, has to be optimized in the therapy of these patients.
AB - Short bowel syndrome is a life threatening disease with a high mortality and morbidity. Since home parenteral nutrition (PN) has been established, there is an increasing number of patients surviving the acute loss of bowel function. But on the long-time these patients suffer from different complications of PN, with loss of central venous access, recurrent sepsis and finally the syndrome of progressive cholestatic liver disease. Both loss of central venous access and especially the progressive cholestatic liver disease are the limiting factor for the long-term survival of patients suffering from intestinal failure. Interestingly, the pathophysiologic mechanisms of PN induced intrahepatic cholestasis have not been dissolved yet and seem to be of multifactorial genesis. Cholestasis has shown to be associated with prematurity, recurrent sepsis, enteral and PN, especially with lipid emulsions. Enteral feeding and a well-controlled regime of PN lower the incidence of end-stage liver disease and, therefore, has to be optimized in the therapy of these patients.
KW - Anti-Bacterial Agents
KW - Child
KW - Cholagogues and Choleretics
KW - Cholestasis
KW - Drug Therapy, Combination
KW - Enteral Nutrition
KW - Evidence-Based Medicine
KW - Humans
KW - Infant, Newborn
KW - Infant, Premature
KW - Intestine, Small
KW - Liver Diseases
KW - Parenteral Nutrition
KW - Parenteral Nutrition, Home
KW - Practice Guidelines as Topic
KW - Prognosis
KW - Risk Factors
KW - Sepsis
KW - Short Bowel Syndrome
KW - Treatment Outcome
KW - Ursodeoxycholic Acid
KW - Journal Article
KW - Review
M3 - SCORING: Journal article
C2 - 19461571
VL - 61
SP - 273
EP - 281
JO - MINERVA PEDIATR
JF - MINERVA PEDIATR
SN - 0026-4946
IS - 3
ER -